Geode Capital Management
CLRB icon

Geode Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Geode Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134K Buy
52,778
+24,142
+84% +$77.9K ﹤0.01% 4055
2025
Q4 		$84.5K Buy
28,636
+3,744
+15% +$13.8K ﹤0.01% 4134
2025
Q3 		$139K Buy
24,892
+10,453
+72% +$51.8K ﹤0.01% 4038
2025
Q2 		$103K Sell
14,439
-342
-2% -$2.99K ﹤0.01% 4053
2025
Q1 		$140K Buy
14,781
+3,085
+26% +$27.9K ﹤0.01% 3941
2024
Q4 		$105K Sell
11,696
-52
-0.4% -$2.4K ﹤0.01% 4087
2024
Q3 		$754K Buy
11,748
+375
+3% +$24.7K ﹤0.01% 3457
2024
Q2 		$853K Buy
11,373
+837
+8% +$80.3K ﹤0.01% 3371
2024
Q1 		$1.26M Buy
10,536
+8,240
+359% +$893K ﹤0.01% 3274
2023
Q4 		$191K Buy
2,296
+201
+10% +$15K ﹤0.01% 3957
2023
Q3 		$166K Buy
2,095
+533
+34% +$31.4K ﹤0.01% 4052
2023
Q2 		$91.4K Sell
1,562
-13
-0.8% -$626 ﹤0.01% 4364
2023
Q1 		$68K Sell
1,575
-26
-2% -$1.27K ﹤0.01% 4451
2022
Q4 		$82K Buy
1,601
+120
+8% +$7.19K ﹤0.01% 4458
2022
Q3 		$149K Hold
1,481
– – ﹤0.01% 4368
2022
Q2 		$179K Buy
1,481
+8
+0.5% +$1.14K ﹤0.01% 4338
2022
Q1 		$303K Hold
1,473
– – ﹤0.01% 4179
2021
Q4 		$293K Hold
1,473
– – ﹤0.01% 4301
2021
Q3 		$408K Buy
1,473
+149
+11% +$45.5K ﹤0.01% 4130
2021
Q2 		$472K Buy
1,324
+509
+62% +$221K ﹤0.01% 3968
2021
Q1 		$393K Buy
815
+374
+85% +$222K ﹤0.01% 3888
2020
Q4 		$275K Buy
+441
New +$203K ﹤0.01% 3788
2018
Q3 		– Sell
-24
Closed -$44K – 4127
2018
Q2 		$44K Buy
+24
New +$73.7K ﹤0.01% 3987
2016
Q1 		– Sell
-1
Closed -$33K – 4100
2015
Q4 		$33K Hold
1
– – ﹤0.01% 4055
2015
Q3 		$88K Buy
+1
New +$91K ﹤0.01% 3924

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Geode Capital Management's CLRB Position: Q1 2026 in Review

Geode Capital Management increased its Cellectar Biosciences (CLRB) stake by 84% in Q1 2026, buying an estimated $77.9K and bringing the position to 52,778 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #4055.

Geode Capital Management first reported a position in CLRB in Q3 2015 and has held it in 25 quarters since. The position peaked at $1.26M in Q1 2024. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • Geode Capital Management held 52,778 shares of Cellectar Biosciences worth $134K as of Q1 2026.
  • Geode Capital Management bought 24,142 Cellectar Biosciences shares in Q1 2026, an estimated $77.9K.
  • Cellectar Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4055 holding.
  • Geode Capital Management first reported a position in Cellectar Biosciences in Q3 2015 and has held it in 25 quarters since.
  • Geode Capital Management's Cellectar Biosciences position peaked at $1.26M in Q1 2024.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.